Lack of access to new cancer medicines in LMICs

Adagrasib shows CNS penetration and encouraging intracranial activity for KRASG12C-mutated NSCLC and active, untreated CNS metastases

Spotlight on global cancer control at ASCO 2022

UICC announces global coalition to increase access to essential cancer medicines in low and lower middle-income countries

Comment: LUMINA results show that women with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy

Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy

Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patients previously treated with a JAK inhibitor

Luminal A-type breast cancer patients with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy

Pembrolizumab demonstrates clinically meaningful improvement in distant metastasis-free survival in patients with melanoma

Elacestrant significantly prolongs PFS for ER+/HER2- metastatic breast cancer without prior chemotherapy patients

Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard of care for resectable stage III melanoma

Pancreatic neuroendocrine tumours: Capecitabine plus temozolomide gives longer PFS than temozolomide alone